Cat. No. 3916
Chemical Name: 6-[(Aminocarbonyl)(2,6-difluorophen
Biological ActivityOrally active, ATP-competitive inhibitor of p38α MAPK; also inhibits p38β (KD values are 3.7 and 17 nM respectively).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Goldstein et al (2010) Selective p38α inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J.Med.Chem. 53 2345. PMID: 19950901.
Damjanov et al (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis. Arthrit.Rheumat. 60 1232.
Din (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr.Opin.Investig.Drugs 7 1020. PMID: 17117592.
If you know of a relevant reference for VX 702 please let us know.
Citations are publications that use Tocris products. Selected citations for VX 702 include:
O'Sullivan et al (2016) Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions inhuman astrocytes. Journal of Neuroinflammation 13 189. PMID: 27549131.
Do you know of a great paper that uses VX 702 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: VX 702, supplier, VX702, orally, active, p38α, p38alpha, p38a, p38β, p38beta, p38b, inhibitors, inhibits, MAPK, Signaling, Signalling, Mitogen-Activated, Protein, Kinases, Tocris Bioscience, p38 MAPK Inhibitor products